We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
GlaxoSmithKline Purchases Illumina's HumanHap550 BeadChips for Large Scale Whole Genome Association Studies
News

GlaxoSmithKline Purchases Illumina's HumanHap550 BeadChips for Large Scale Whole Genome Association Studies

GlaxoSmithKline Purchases Illumina's HumanHap550 BeadChips for Large Scale Whole Genome Association Studies
News

GlaxoSmithKline Purchases Illumina's HumanHap550 BeadChips for Large Scale Whole Genome Association Studies

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "GlaxoSmithKline Purchases Illumina's HumanHap550 BeadChips for Large Scale Whole Genome Association Studies"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Illumina, Inc. has announced that it entered into a multi-million dollar agreement with GlaxoSmithKline (GSK) for the purchase of 1,000 HumanHap550 BeadChips to be run at an undisclosed third-party facility and the addition of a statement of work to utilize Illumina's Fast-Track Genotyping Service to process approximately 4,000 disease samples for pharmacogenetics application.

According to Illumina, by the end of 2006, it will have genotyped more than 15,000 samples and reported nearly 3.5 billion genotypes to GSK.

"This purchase follows shortly after GlaxoSmithKline expanded their initial scope of work for a multi-year, genotyping services agreement with Illumina, demonstrating their continued uptake of our technology," said Jay Flatley, Illumina President and Chief Executive Officer.

Advertisement